-Ipsen now part of the largest association of biotechnology companies,
academic institutions and biotech centers –
CAMBRIDGE, MA, October 3, 2018 – Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced it has joined the Biotechnology Innovation Organization (BIO), the largest association of biotechnology companies, academic institutions and biotech centers around the world, and a leader in biotech innovation for over a quarter of a century. As a member of this global community, Ipsen will be among a network of member industry peers across the life sciences ecosystem to improve the lives of patients and propel both the company and industry into a new era.
“We are proud to join this group of progressive industry leaders, policymakers and researchers who actively share in our desire to encourage investment in and promotion of biotechnology research and development,” said Richard Paulson, Chief Executive Officer of Ipsen North America. “We look forward to strengthening and growing the biotech industry together—developing innovative medicines, advancing critical healthcare policies and business practices, and forging partnerships that will result in solutions for patients in need.”
Aligned with BIO’s strategic focus on enriching the industry with networking, partnering and education opportunities, Ipsen has placed external innovation and partnerships at the forefront of its growth strategy. Ipsen recently announced the consolidation of its North American business, creating a fully integrated presence, in its new global hub in Cambridge’s Kendall Square—the most innovative square mile in the world, with hundreds of biopharma, venture capital and start-up companies.
“Ipsen’s commitment to improving patients’ lives and medical innovation is a natural extension of BIO’s mission to harness the power of biology and technology to improve the lives and health of people around the world,” said Jim Greenwood, BIO President and Chief Executive Officer. “By building our network of partnerships with leading biotech companies like Ipsen, we move closer to achieving our combined goal of unleashing the power of scientific innovation to help solve patient needs.”
In addition to membership with BIO, Ipsen also holds longstanding relationships with a number of associations, including Pharmaceutical Research and Manufacturers of America (PhRMA), the National Pharmaceutical Council (NPC), Massachusetts Biotechnology Council, BioNJ, Innovative Medicines Canada, and the Organization for International Investment. Additionally, Ipsen Group is a member of both the European Federation of Pharmaceutical Industries and Associations and the International Federation of Pharmaceutical Manufacturers and Associations.
Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
Ipsen Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes,” “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2017 Registration Document available on its website (www.ipsen.com).
Vice President, NA Communications
© 2018 Ipsen Biopharmaceuticals, Inc.